Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Division of Infectious Diseases and HIV Medicine, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
J Viral Hepat. 2023 Jul;30(7):621-629. doi: 10.1111/jvh.13838. Epub 2023 Apr 21.
Stigma associated with hepatitis B virus (HBV) is common in endemic countries; however; instruments are lacking to accurately measure HBV-related stigma. We therefore aimed to develop and validate a concise instrument for measuring perceived HBV-related stigma in Sierra Leone. We enrolled 220 people living with HBV (PWHB) aged ≥18 years from August to November 2022. The initial Likert-scale instrument entailed 12 items adapted from Berger's HIV Stigma Scale. We included four additional items adapted from the USAID indicators for enacted stigma. The proposed scale's psychometric properties were assessed. After item reduction, the final HBV Stigma Scale consisted of 10 items and had good internal consistency (overall Cronbach's α = 0.74), discriminant, and construct validity. Exploratory factor analysis produced a three-dimensional structure accounting for 59.3% of variance: personalized stigma driven by public attitudes (six items), negative self-image (two items), and disclosure concerns (two items). Overall, 72.8% of respondents reported perceived HBV-related stigma (mean score 29.11 ± 4.14) and a similar proportion (73.6%) reported at least one instance of enacted stigma. In assessing criterion-related validity, perceived HBV-related stigma correlated strongly with enacted stigma (r = 0.556) and inversely with having family/friends with HBV (r = -0.059). The 10-item HBV Stigma Scale demonstrated good internal consistency and validity and is suitable for screening for HBV-related stigma in Sierra Leone. The psychometric properties of the scale can be optimized with item additions/modifications and confirmatory factor analysis. The scale may help in combating stigma as a barrier to achieving HBV global elimination goals.
乙型肝炎病毒(HBV)相关耻辱感在流行地区很常见;然而,缺乏准确测量 HBV 相关耻辱感的工具。因此,我们旨在开发和验证一种用于测量塞拉利昂 HBV 相关耻辱感的简洁工具。我们于 2022 年 8 月至 11 月招募了 220 名年龄≥18 岁的 HBV 感染者(PWHB)。最初的李克特量表工具包含 12 个项目,改编自 Berger 的 HIV 耻辱量表。我们还纳入了 4 个来自美国国际开发署实施耻辱感指标的项目。评估了拟议量表的心理测量特性。经过项目删减,最终的 HBV 耻辱量表由 10 个项目组成,具有良好的内部一致性(总 Cronbach's α=0.74)、区分度和结构效度。探索性因子分析产生了一个三维结构,占 59.3%的方差:受公众态度驱动的个性化耻辱感(六个项目)、消极的自我形象(两个项目)和披露顾虑(两个项目)。总体而言,72.8%的受访者报告存在 HBV 相关耻辱感(平均得分 29.11±4.14),相似比例(73.6%)报告至少有一次实施耻辱感的经历。在评估效标相关效度时,HBV 相关耻辱感与实施耻辱感呈强相关(r=0.556),与有 HBV 家庭/朋友呈负相关(r=-0.059)。10 项 HBV 耻辱量表具有良好的内部一致性和有效性,适用于筛查塞拉利昂的 HBV 相关耻辱感。通过项目添加/修改和验证性因子分析,可以优化量表的心理测量特性。该量表可能有助于消除耻辱感这一实现 HBV 全球消除目标的障碍。